Isis discontinues development of ISIS-CRPRx for rheumatoid arthritis

08/6/2013 | Reuters

Isis Pharmaceuticals is halting development of its investigational drug ISIS-CRPRx as a treatment for rheumatoid arthritis based on the findings of a Phase II study. The drug failed to significantly outperform a placebo in the alleviation of symptoms. The firm will continue to develop the drug for other diseases, including atrial fibrillation.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI